分子病理常规检测中的事件频率与原因
该研究收集了8家欧洲机构2018年常规进行非小细胞肺癌和结直肠癌生物标志物检测全过程中记录的所有事件,共5185起,其中84.1%发生在分析前前阶段,主要为申请单信息缺失或错误。仅5.7%的事件记录于分析后后阶段,且分析前前阶段事件解决更快(平均6天 vs 60天)。结论强调申请单和最终报告的正确性与完整性极易出错,需额外关注。
要点
- 分子病理检测全过程中分析前前阶段事件占比最高(84.1%),多与申请单信息缺失或错误相关。
- 分析前前阶段事件平均解决时间(6天)短于全过程事件(60天)。
- 仅23.5%的已知原因事件在记录之外采取了具体改进措施。
核心结论
- 分子病理检测中记录的事件数量和范围差异大,申请单和最终报告的正确性与完整性极易出错,需额外关注。
研究设计与样本
- 从8家欧洲常规开展非小细胞肺癌和结直肠癌生物标志物检测的机构收集2018年所有医院服务中生物标志物检测前的前前分析条目及生物标志物检测特定事件。
主要发现
- 共收集5185起事件,其中4363起(84.1%)发生在分析前前阶段(所有医院服务),2796/4363起(64.1%)与申请单信息缺失或错误相关。
- 其余822起特定事件中,分析前阶段166起(20.2%),分析阶段275起(33.5%),分析后阶段194起(23.6%),主要因报告内容不正确。
- 分析后后阶段仅47/822起(5.7%),全过程123起(15.0%),时间点未知17/822起(2.1%)。
- 分析前前阶段事件解决快于全过程事件(平均6天 vs 60天)。
- 5168起已知原因事件中1215起(23.5%)在记录之外采取了具体措施,不限于认证机构。
临床怎么用
- 应重点关注申请单信息的正确性与完整性,以减少分析前前阶段事件。
- 需加强最终报告内容的审核,降低分析后阶段错误。
- 对已知原因的事件除记录外应积极采取具体改进措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT.—: Errors in laboratory medicine could compromise patient safety. Good laboratory practice includes identifying and managing nonconformities in the total test process. Varying error percentages have been described in other fields but are lacking for molecular oncology. OBJECTIVES.—: To gain insight into incident causes and frequency in the total test process from 8 European institutes routinely performing biomarker tests in non-small cell lung cancer and colorectal cancer. DESIGN.—: All incidents documented in 2018 were collected from all hospital services for pre-preanalytical entries before the biomarker test, as well as specific incidents for biomarker tests. RESULTS.—: There were 5185 incidents collected, of which 4363 (84.1%) occurred in the pre-preanalytical phase (all hospital services), 2796 of 4363 (64.1%) related to missing or incorrect request form information. From the other 822 specific incidents, 166 (20.2%) were recorded in the preanalytical phase, 275 (33.5%) in the analytical phase, and 194 (23.6%) in the postanalytical phase, mainly due to incorrect report content. Only 47 of 822 (5.7%) incidents were recorded in the post-postanalytical phase, and 123 (15.0%) in the complete total test process. For 17 of 822 (2.1%) incidents the time point was unknown. Pre-preanalytical incidents were resolved sooner than incidents on the complete process (mean 6 versus 60 days). For 1215 of 5168 (23.5%) incidents with known causes a specific action was undertaken besides documenting them, not limited to accredited institutes. CONCLUSIONS.—: There was a large variety in the number and extent of documented incidents. Correct and complete information on the request forms and final reports are highly error prone and require additional focus.
引用
- Keppens C, Van Royen Y, Brysse A, et al. Incidents in Molecular Pathology: Frequency and Causes During Routine Testing. Arch Pathol Lab Med. 2021. PMID: 33406246. doi:10.5858/arpa.2020-0152-OA
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。